College of Law > About > Centers & Institutes > Center for Intellectual Property Law & Information Technology > The Jaharis Podcast on Health & IP
Click on the podcast titles below to listen or download the episodes on iTunes.
IntroductionWelcome to the Jaharis Podcast!
To the Moonshot and Beyond: Cancer and IP
Featuring Jacob Sherkow from New York Law School
Jacob Sherkow from the New York School of Law is our first guest. His recent work focuses on intellectual property and information policy issues surrounding efforts to cure cancer. We discuss patents, the role of public-private partnerships in cancer R&D and the Cancer Moonshot Initiative.
Exploring the Microbiome
Featuring Rachel Sachs from Washington University Law
In this episode we explore the microbiome -- the world of microbes inside your body. Rachel Sachs from the Washington University School of Law in Saint Louis joins us to discuss intellectual property issues surrounding the microbiome, including emerging treatments and therapies that are starting to take advantage of microbiome research.
Fighting Antibiotic Resistance
Featuring Kevin Outterson, Executive Director of CARB-X
More than 23,000 people die every year in the US from antibiotic-resistant bacteria. We welcome to the podcast Kevin Outterson, executive director of CARB-X (Combating Antibiotic Resistance Bacteria Biopharmaceutical Accelerator), a USD 450 million partnership that is taking the lead in protecting humanity from bacterial threats.
Federally Funded Research: Approaching Four Decades of the Bayh-Dole Act
Featuring Lisa Ouellete, Associate Professor at Stanford Law School
In 1980, Congress enacted the Bayh-Dole Act, which is often considered the "basis of the biotech revolution." In this episode, we explore the impact of patents on federally funded research at universities and other institutions in the wake of Bayh-Dole with Lisa Ouellete, who has written extensively on the topic.
Medicine of the Future: From Biologics to Black Box Medicine
Featuring Nicholson Price, Assistant Professor of Law at University of Michigan Law School
Biologics are often hailed as the most promising drugs currently available to patients. However, they are extraordinarily difficult to replicate, a feature that poses unique problems to competitors and regulators. Today we talk with Nicholson Price about this issue and about “black box” medicine: what happens when we rely on algorithms for diagnostics or to identify therapies?
Investor-State Arbitration and “Alternative Facts” in Pharmaceutical Marketing
Featuring Cynthia Ho, Clifford E. Vickrey Research Professor and Director, Intellectual Property Program at Loyola University Chicago School of Law
Cynthia Ho provides an overview of two different fields with implications for public health. We start by discussing international agreements that allow foreign companies to bring claims against states on the grounds that their investments—including those in the form of intellectual property, such as pharmaceutical patents—have been compromised. We then talk about Cynthia’s latest article, in which she argues that, in some situations, pharmaceutical marketing to doctors may be considered “alternative facts” and therefore entitled to less First Amendment protection.
Loop Campus25 E. Jackson Blvd.Chicago, IL 60604(312) 362-8701
2001-2014 DePaul University | Disclaimer | Contact Us | Emergency Plan | Consumer Information | Privacy StatementEditor Login